ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2025
Effect of citrus essential oil petit grain in growth and motility reduction of hypopharyngeal squamous cell carcinoma (FaDu) in vitro model.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundPetit grain (PGO), a citrus essential oil (EO), isolated from the twigs and leaves of bitter orange (citrus arantiun), has been shown to have different beneficial properties, such as antibacterial, anti-fungal, anti-viral, anti-inflammatory and anti-cancer properties. Hypopharyngeal carcinoma is typically treated with combination radiotherapy and chemotherapy (cisplatin). However, resistance to cisplatin may lead to other new treatments, such as immunotherapy, which can be well-tolerated and potentially beneficial. PURPOSE: In this study, PGO was proposed as a natural growth-regulating molecule of the FaDu cell line from hypopharyngeal squamous cell carcinoma.
methodsThe study used MTT assay, growth curves, Western blot, and FACS analysis to assess the impact of PGO on petit grain cell growth, protein levels, and cell cycle phases.
resultsThe potent cytotoxic effect of PGO against FaDu was demonstrated by its low IC50. Daily administration of 0.025% (v/v) and 0.5% (v/v) PGO on FaDu cells resulted in a time and dose-dependent decrease in cell viability and growth. PGO caused a cell cycle arrest in the G1/S transition phase, which was verified by increased expression of cell cycle regulating proteins p27, p21 and p18, and a decrease of CDK2 and CDK4 proteins. PGO treatment also reduced the phosphorylation of the proliferative signals pAKT. Last but not least, PGO dramatically increased the sensitivity of FaDu cells to chemotherapy when combined with cis-platin, the usual treatment for squamous cell carcinoma.
conclusionSince PGO inhibits the growth of FaDu squamous carcinoma cells through a variety of combined mechanisms, it could be considered as a promising adjuvant therapy for this complex disease.
Indexed as
Identifiers
40397313What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.